Clover Health (CLOV) director granted 79,365 RSUs shares vesting 2027

Rhea-AI Filing Summary

Clover Health Investments, Corp. director William G. Robinson Jr reported an equity award of 79,365 shares of Class A common stock on January 6, 2026. These shares represent time-based restricted stock units that will vest in full on the first anniversary of January 6, 2026, as long as he continues to serve as a director through that date. The award was recorded at a price of $0 per share, reflecting a grant rather than an open-market purchase. After this grant, Robinson beneficially owned a total of 597,987 shares of Class A common stock in direct ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robinson William G Jr

(Last) (First) (Middle)

C/O CLOVER HEALTH INVESTMENTS, CORP.

NOT APPLICABLE

(Street)

WILMINGTON DE 19801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	01/06/2026		A		79,365(1)	A	$0	597,987	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Class A Common Stock underlying an award of time-based restricted stock units (RSUs). The RSUs will vest in full on the first anniversary of January 6, 2026, subject to the Reporting Person's continued service as a director through such vesting date.

Remarks:

	/s/Peter J. Rivas as attorney-in-fact for William G. Robinson, Jr.	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who reported a transaction in Clover Health (CLOV) in this Form 4?

The reporting person is William G. Robinson Jr, who serves as a director of Clover Health Investments, Corp. and filed the Form 4 as a single reporting person.

What type of security did William G. Robinson Jr acquire in Clover Health (CLOV)?

He acquired Class A Common Stock of Clover Health Investments, Corp., delivered in the form of time-based restricted stock units (RSUs) that settle into Class A shares.

How many Clover Health (CLOV) shares were granted to the director and at what price?

On January 6, 2026, he was granted 79,365 shares of Class A Common Stock underlying RSUs at a reported price of $0 per share, consistent with an equity compensation award rather than a market trade.

When do the Clover Health (CLOV) RSUs granted to the director vest?

The RSUs will vest in full on the first anniversary of January 6, 2026, provided that the reporting person continues to serve as a director through that vesting date.

How many Clover Health (CLOV) shares does the director own after this grant?

Following the reported transaction, the Form 4 shows that the director beneficially owned 597,987 shares of Class A Common Stock, held with direct ownership.

Was this Clover Health (CLOV) Form 4 transaction a sale or a purchase on the market?

No public market sale or purchase is indicated. The Form 4 reports an “A” (acquired) transaction code at $0 per share, reflecting an equity award of RSU-based Class A Common Stock as director compensation.